GlassScriptPhysician profile
Abby M Nasternak
NPI 1689645467
$5,063.31
in general payments reported to CMS, 2019-2025
24 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,570 · 2022: $787 · 2023: $1,126 · 2024: $579 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,855.38 | 2021-2025 | |
| Revance Therapeutics, INC. | $462.02 | 2025 | Daxxify, Daxi |
| Gilead Sciences, INC. | $332.70 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $259.73 | 2021 | |
| Janssen Scientific Affairs, LLC | $234.08 | 2021-2024 | Tremfya |
| Lilly USA, LLC | $215.45 | 2023-2025 | Mounjaro, Zepbound |
| Medical Device Business Services, INC. | $209.48 | 2022 | |
| Ferring Pharmaceuticals INC. | $160.28 | 2021-2023 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.30 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $148.41 | 2021-2025 | Entyvio |
| Inari Medical, INC. | $144.07 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ardelyx, INC. | $130.92 | 2023 | Ibsrela |
| Qol Medical, LLC | $128.05 | 2021 | |
| Grifols USA, LLC | $125.00 | 2023 | Hyperrab |
| Daiichi Sankyo INC. | $121.75 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $115.93 | 2022-2023 | |
| Madrigal Pharmaceuticals | $106.70 | 2025 | Rezdiffra |
| Csl Behring | $37.22 | 2024 | Kcentra |
| Corium, LLC | $28.67 | 2023 | Azstarys |
| Pfizer INC. | $25.85 | 2022 | |
| Lucid Diagnostics INC. | $17.90 | 2021 | |
| Janssen Biotech, INC. | $17.52 | 2021 | |
| Novo Nordisk INC | $14.18 | 2025 | Ozempic, Rybelsus |
| W. L. Gore & Associates, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Nasternak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.